BioStock Studio: Scandion Oncology brings in New CEO

Scandion Oncology’s top candidate, SCO-101, is currently in a phase II clinical trial with metastatic colorectal cancer patients. As the study progresses, the company is beginning a new phase in its development program. In light of this, the company has appointed Bo Rode Hansen as CEO, while former CEO Nils Brunner takes the role as CSO, to strengthen its executive leadership. Both Rode Hansen and Brunner came to the BioStock studio to discuss the change.

Watch the full interview with Scandion Oncology's CEO Bo Rode Hansen and CSO Nils Brünner at biostock.se:

https://www.biostock.se/en/biostock-studio-scandion-oncology-brings-in-new-ceo/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se